ALTUVIIIO is a first-in-class, high-sustained factor VIII replacement therapy which provides highly effective bleed protection in adults and children with hemophilia A Approval demonstrates commitment ...

Preliminary Class 8 orders in April declined to 7,400 units, according to FTR Transportation Intelligence – a 54% decline both month-over-month and year-over-year and the lowest monthly total since ...

[Stay on top of transportation news: Get TTNews in your inbox.] North American Class 8 truck orders continued to trend below the year-ago period in August, according to ACT Research. ACT preliminary ...

Paris and Stockholm – February 23, 2023 – The U.S. Food and Drug Administration (FDA) has approved ALTUVIIIO™ [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl], previously ...